Gene-modified mesenchymal stem cells express functionally active nerve growth factor on an engineered poly lactic...

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Neuroscience

Background:

• Peripheral nerve and spinal cord injuries impede neural repair.
• Delivering therapeutic cells and neurotrophic factors can promote neural regeneration.
• Engineered scaffolds offer a platform for localized delivery of these agents.

Purpose of the Study:

• To genetically engineer mesenchymal stem cells (MSCs) to express nerve growth factor (NGF).
• To evaluate the viability, phenotype, and differentiation capacity of engineered MSCs.
• To assess the functional activity of NGF secreted by engineered MSCs for neural repair.

Main Methods:

• Mesenchymal stem cells (MSCs) were genetically modified using an adenoviral vector to express nerve growth factor (NGF).
• Engineered MSCs were cultured on poly-lactic-co-glycolic acid (PLGA) scaffolds.
• Cell phenotype, viability, differentiation potential, and NGF secretion levels (ELISA) were analyzed.
• Functional activity of secreted NGF was tested using a PC12 neurite growth assay.

Main Results:

• Engineered MSCs maintained their stem cell phenotype (CD71, CD172 positive; CD45 negative) and expressed green fluorescent protein (GFP) long-term.
• Cells remained viable and retained differentiation capacity (chondrogenic, osteogenic, adipogenic) on PLGA scaffolds.
• MSCs secreted functionally active NGF at physiologically relevant concentrations (~25 ng/mL).

Conclusions:

• Genetically engineered MSCs are a promising cell-based delivery system for therapeutic factors in neural repair.
• MSCs are autologous, amenable to genetic modification for neurotrophin expression, and compatible with polymer scaffolds.
• This approach holds potential for treating peripheral nerve and spinal cord injuries.